Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis-Reference-Cited by-同舟云学术

Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis

Published:2005-12 Issue:1 Volume:239 Page:95-99
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Tortorella Carla,Bellacosa Alessandra,Paolicelli Damiano,Fuiani Aurora,Di Monte Elisabetta,Simone Isabella Laura,Giaquinto Patrizia,Livrea Paolo,Trojano Maria

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology

Reference33 articles.

1. Duration and selectivity of blood brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers;Hawkins;Brain,1990

2. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema;Morrissey;Brain,1996

3. Multiple sclerosis: gadolinium enhancement in MR imaging;Grossman;Radiology,1986

4. Correlation between magnetic resonance imaging findings and lesion development in chronic active multiple sclerosis;Katz;Ann Neurol,1993

5. Multiple sclerosis: histopathological and MR and/or CT correlation in 37 cases at biopsy and 3 cases at autopsy;Nesbit;Radiology,1991

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selecting informative patients for phase 2 progressive trials in MS: Design considerations for phase 2 clinical trials in progressive MS;Multiple Sclerosis Journal;2024-09-08

2. Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations;Multiple Sclerosis Journal;2024-09-08

3. De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis;Current Neurology and Neuroscience Reports;2024-07-12

4. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS;JAMA Neurology;2024-05-01

5. Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study;Journal of Neurology, Neurosurgery & Psychiatry;2024-04-03